BSE · 524075 · Pharmaceuticals
Albert David Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹341 Cr with net profit ₹-1 Cr — a -0.44% net margin, versus 4.58% the period before.
Shareholding
As of 2026-09-30
- Promoter62.24%
- Public35.53%
- FII0.6%
- DII1.64%
12,709 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.59× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #61 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,21,683 Cr | 33.37 | 5.05 | 13.74% | 20.29% |
| Laurus Labs Limited | ₹1,17,891 Cr | 107.8 | 22.24 | 16.77% | 15.04% |
| Zydus Lifesciences Ltd. | ₹1,17,257 Cr | 24.01 | 4.33 | 18.59% | 16.09% |
| Dr Reddys Laboratories Ltd. | ₹1,11,463 Cr | 39.82 | 2.87 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,10,323 Cr | 35.53 | 3.12 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,02,848 Cr | 44.08 | 5.85 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹94,638 Cr | 25.03 | 2.5 | 9.25% | 10.7% |
| Lupin Limited | ₹90,210 Cr | 15.15 | 4.02 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹64,912 Cr | 20.8 | 6.17 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,619 Cr | 26.6 | 4.39 | 16.66% | 14.31% |
| Albert David Ltd.(this company) | ₹438 Cr | 19.42 | 1.12 | -38.18% | 6.19% |
AI analysis
AI-generated · google/gemini-2.5-flashAlbert David Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 395 Cr. The company reported a negative profit margin of -44.66% and a negative return on equity (ROE) of -38.18%. Its debt-to-equity ratio stands at 0.05. The promoter holding as of June 2026 was 62.2369%.
Positives
- +The company's debt-to-equity ratio is low at 0.05.
- +Promoter holding of 62.2369% as of June 2026 indicates significant insider interest.
- +No shares are reported to be pledged by the promoters.
Negatives
- −The company reported a negative net profit of -1.4947 Cr in Mar 2026.
- −Albert David Ltd. has a negative profit margin of -44.66%.
- −Return on equity (ROE) is negative at -38.18%.
- −Annual revenue decreased to Rs 341.0514 Cr in Mar 2026 from Rs 375.3487 Cr in Mar 2025.
- −The latest twelve-month EPS is 0, indicating no earnings over this period.
Financial performance
Albert David Ltd. reported annual revenue of Rs 341.0514 Cr in Mar 2026, a decrease from Rs 375.3487 Cr in Mar 2025. The net profit for Mar 2026 was -1.4947 Cr, down from 17.2008 Cr in the previous year. Earnings per share (EPS) also declined to -2.62 in Mar 2026 from 30.14 in Mar 2025.
Profitability & returns
The company's profitability has seen a decline, with a negative profit margin of -44.66%. Return on equity (ROE) was -38.18%, and return on capital employed (ROCE) was 0.7495%. The EPS for Mar 2026 was -2.62, representing a decrease from positive EPS in prior years.
Balance sheet
Albert David Ltd. maintains a low debt-to-equity ratio of 0.05. The book value per share is 685.71. Further details on the balance sheet structure, beyond debt-to-equity, are not available in the provided data.
Ownership & pledges
The promoter holding in Albert David Ltd. was 62.2369% as of June 2026. Public shareholders held 35.562% of the company, while FIIs held 0.5654% and DIIs held 1.6357%. There were no promoter shares reported as pledged.
Data as of — price: 2026-10-28 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.